Overview

Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults

Status:
COMPLETED
Trial end date:
2024-09-02
Target enrollment:
Participant gender:
Summary
This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.
Phase:
PHASE1
Details
Lead Sponsor:
Pharmosa Biopharm Inc.
Collaborator:
Novotech (Australia) Pty Limited